<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749202</url>
  </required_header>
  <id_info>
    <org_study_id>PRV-10001</org_study_id>
    <nct_id>NCT01749202</nct_id>
  </id_info>
  <brief_title>Effects of Stearidonic Acid-Containing Foods on Eicosapentaenoic Acid Levels in Red Blood Cells and Omega-3 Index</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solae, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Provident Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Solae, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of stearidonic acid when used as a food&#xD;
      ingredient on eicosapentaenoic enrichment of red blood cell membranes and Omega-3 Index in&#xD;
      men and women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End of treatment EPA level in RBC membranes, expressed as a percent of total RBC membrane fatty acids</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Omega-3 Index</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDA percent of total RBC membrane fatty acids</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA (IR) and HOMA (%B)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Sudden Cardiac Death</condition>
  <condition>Sudden Cardiac Arrest</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Negative Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sunflower Oil Softgels</intervention_name>
    <description>3 x 500 mg softgel capsules/day</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Negative Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EPA softgels</intervention_name>
    <description>3 x 500 mg softgel capsules/day</description>
    <arm_group_label>Positive Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sunflower Oil Food</intervention_name>
    <description>3 servings/day</description>
    <arm_group_label>Negative Control</arm_group_label>
    <arm_group_label>Positive Control</arm_group_label>
    <other_name>Food</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SDA soybean Oil Food</intervention_name>
    <description>3 servings/day</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Food</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 21 to 65 years of age.&#xD;
&#xD;
          2. BMI) ≥18.00 and &lt;40.00 kg/m2.&#xD;
&#xD;
          3. No health conditions that would prevent him/her from fulfilling the study requirements&#xD;
             as judged by the Investigator on the basis of medical history and routine laboratory&#xD;
             test results.&#xD;
&#xD;
          4. Willing to avoid alcohol consumption for 24 h prior to every clinic visit.&#xD;
&#xD;
          5. No plans to change smoking habits during the study period.&#xD;
&#xD;
          6. Willing to maintain a stable body weight, activity level and dietary pattern except&#xD;
             for use of the study products, as directed.&#xD;
&#xD;
          7. Understands the study procedures and signs forms providing informed consent to&#xD;
             participate in the study and authorization for release of relevant protected health&#xD;
             information to the study Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has coronary heart disease or a coronary heart disease risk equivalent&#xD;
             including any of the following:&#xD;
&#xD;
               -  Diabetes mellitus&#xD;
&#xD;
               -  Clinical signs of atherosclerosis including peripheral arterial disease,&#xD;
                  abdominal aortic aneurysm, carotid artery disease&#xD;
&#xD;
               -  Presence of multiple risk factors that give a person a greater than 20% chance&#xD;
                  for developing coronary artery disease within 10 years.&#xD;
&#xD;
          2. Abnormal laboratory test results of clinical significance&#xD;
&#xD;
          3. TG ≥400 mg/dL at visit 1, week -2.&#xD;
&#xD;
          4. Smokes more than one pack of cigarettes (20 cigarettes) per day.&#xD;
&#xD;
          5. History or presence of clinically important renal, hepatic, pulmonary, biliary,&#xD;
             gastrointestinal, neurologic or endocrine disorders that in the judgment of the&#xD;
             Investigator, would interfere with the subject's ability to provide informed consent,&#xD;
             comply with the study protocol Stable, treated hypothyroidism is allowed.&#xD;
&#xD;
          6. Uncontrolled hypertension&#xD;
&#xD;
          7. Unstable use within four weeks of visit 1 (week -2) of antihypertensive medications or&#xD;
             thyroid hormone replacement.&#xD;
&#xD;
          8. Use of any lipid-altering drugs, including statins, bile acid sequestrants,&#xD;
             cholesterol absorption inhibitors, fibrates, or prescription formulations of niacin&#xD;
             within four weeks of visit 1 (week -2) and throughout the study. If a subject needs to&#xD;
             wash off of a drug, he/she will be consented and then asked to return after the four&#xD;
             week washout.&#xD;
&#xD;
          9. Use of EPA/DHA from a drug or supplement within four months of visit 1&#xD;
&#xD;
         10. Frequent use (more than twice per month) of any non-study-related EPA/DHA containing&#xD;
             enriched foods (such as DHA-enriched eggs) within four months of visit 1, week -2 and&#xD;
             avoidance of these enriched foods throughout the study period&#xD;
&#xD;
         11. Use of seeds and oils containing a significant amount of ALA&#xD;
&#xD;
         12. Consumption of fatty fish (salmon, herring, mackerel, albacore tuna, or sardines) more&#xD;
             than twice per month&#xD;
&#xD;
         13. Use of any dietary supplement known to alter lipid metabolism&#xD;
&#xD;
         14. Use of any weight-loss medication&#xD;
&#xD;
         15. Use of any weight loss supplement or program within four weeks of visit 1&#xD;
&#xD;
         16. Known allergy or sensitivity to study products or any ingredients of the study&#xD;
             products.&#xD;
&#xD;
         17. Subject is unwilling to consume the study products (bars, beverages and capsules)&#xD;
             based on results from the taste testing of the study products at visit 1, week -2.&#xD;
&#xD;
         18. Subject has a history or presence of cancer in the prior two years, except for&#xD;
             non-melanoma skin cancer&#xD;
&#xD;
         19. Females who are pregnant, planning to be pregnant during the study period, lactating,&#xD;
             or women of childbearing potential who are unwilling to commit to the use of a&#xD;
             medically approved form of contraception throughout the study period. The method of&#xD;
             contraception must be recorded in the source documentation.&#xD;
&#xD;
         20. Current or recent history of (within 12 months of visit 1, week -2) or strong&#xD;
             potential for alcohol or substance abuse. Alcohol abuse will be defined as &gt;14 drinks&#xD;
             per week (1 drink = 12 oz beer, 5 oz wine, or 1 ½ oz distilled spirits).&#xD;
&#xD;
         21. Exposure to any non-registered drug product within 30 days prior to the screening&#xD;
             visit (visit 1, week -2).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ratna Mukherjea, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Solae, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Provident Clinical Research &amp;Consulting</name>
      <address>
        <city>Glen Ellyn</city>
        <state>Illinois</state>
        <zip>60137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>June 15, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2012</study_first_posted>
  <last_update_submitted>December 11, 2012</last_update_submitted>
  <last_update_submitted_qc>December 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Omega 3 fatty acids</keyword>
  <keyword>Omega 3 Index</keyword>
  <keyword>Stearidonic acid (SDA)</keyword>
  <keyword>Red Blood Cells</keyword>
  <keyword>Lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

